Ross River Virus Seroprevalence, French Polynesia, 2014–2015

Aubry, Maïté; Teissier, Anita; Huart, Michael; Merceron, Sébastien; Vanhomwegen, Jessica; Roche, Claudine; Vial, Anne-Laure; Teururai, Sylvianne; Sicard, Sébastien; Paulous, Sylvie; Desprès, Philippe; Manuguerra, Jean-Claude; Mallet, Henri‐Pierre; Musso, Didier; Deparis, Xavier; Cao-Lormeau, Van-Mai

doi:10.3201/eid2310.170583

Cited by 17 publications

(17 citation statements)

References 10 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors reported ZIKV seroprevalence of 36.1% (95% confidence interval, CI: 34.5; 37.8%) among the 2-14 year age group and 56.4% (95% CI: 53.1; 59.6%) among the 15-80 year age group [23,24]. The observed post-outbreak seroprevalence in adults is in line with findings from seroprevalence studies from French Polynesia, Brazil, and Bolivia [25][26][27].…”

Section: Introductionsupporting

confidence: 74%

Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak

et al. 2019

View full text Add to dashboard Cite

The 2015-2017 epidemics of Zika virus (ZIKV) in the Americas caused widespread infection, followed by protective immunity. The timing and burden of the next Zika virus outbreak remains unclear. We used an agent-based model to simulate the dynamics of age-specific immunity to ZIKV, and predict the future age-specific risk using data from Managua, Nicaragua. We also investigated the potential impact of a ZIKV vaccine. Assuming lifelong immunity, the risk of a ZIKV outbreak will remain low until 2035 and rise above 50% in 2047. The imbalance in age-specific immunity implies that people in the 15-29 age range will be at highest risk of infection during the next ZIKV outbreak, increasing the expected number of congenital abnormalities. ZIKV vaccine development and licensure are urgent to attain the maximum benefit in reducing the population-level risk of infection and the risk of adverse congenital outcomes. This urgency increases if immunity is not lifelong.

show abstract

Section: Introductionsupporting

confidence: 74%

Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The authors reported ZIKV seroprevalence of 36.1% (95% confidence interval, CI: 34.5; 37.8%) among the 2-14 year age group and 56.4% (95% CI: 53.1; 59.6%) among the 15-80 year age group (Zambrana et al, 2018; Balmaseda et al, 2017). The observed post-outbreak seroprevalence in adults is in line with findings from seroprevalence studies from French Polynesia, Brazil, and Bolivia (Aubry et al, 2017; Netto et al, 2017; Saba Villarroel et al, 2018).…”

Section: Introductionsupporting

confidence: 88%

“…Other analyses, based on incidence data only, resulted in higher 𝓡 0 values and predicted very high post-epidemic seroprevalence levels, e.g. 87-97% in (Kucharski et al, 2016), which were contradicted by later seroprevalence studies (49% observed (Aubry et al, 2017)). Other authors dealt with this discrepancy by removing the assumption of homogeneous mixing, allowing for a proportion of the population to be excluded from participating in the epidemic (Champagne et al, 2016).…”

Section: Discussionmentioning

confidence: 89%

“…Thus, vaccine development efforts should be increased. Our conclusions are drawn based on data from Managua, Nicaragua, but should be relevant to many regions in the Americas and the Pacific that have documented high post-epidemic levels of seropositivity (Aubry et al, 2017; Netto et al, 2017; Saba Villarroel et al, 2018). In regions where ZIKV has not yet caused an epidemic but competent vectors are present, vaccination would be in place as well.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak

Counotte

Althaus

Low

et al. 2019

Preprint

View full text Add to dashboard Cite

9Zika virus (ZIKV) is a mosquito-borne flavivirus. In 2016, Managua, the capital city of 10 Nicaragua experienced a Zika virus outbreak. Amongst confirmed cases, seropositivity increased 11 with age and >50% of the adult population had ZIKV antibodies. The duration of immunity 12 to ZIKV remains unclear. We used an agent-based model in a Bayesian framework to describe 13 the dynamics of immunity to ZIKV, and predict the future age-specific risk of ZIKV infection 14 in the population of Managua. We also investigated the potential impact of a ZIKV vaccine 15 under different assumptions about the persistence of immunity. Assuming lifelong immunity, 16 the risk of a ZIKV outbreak will remain low until 2035 and rise above 50% in 2047. Young 17 women of reproductive age will be at highest risk of infection during the next ZIKV outbreak. 18ZIKV vaccine development and licensure are urgent, to attain the maximum benefit in reducing 19 the population-level risk of infection and the risk of adverse congenital outcomes. 20

show abstract

“…Additionally, other alphaviruses predicted to be important emerging agents have been successfully inactivated by amotosalen/UVA‐PRT in PC. The high sensitivity of alphaviruses to treatment was confirmed with Ross River virus, which had an LRF of >5.1 log, and Mayaro virus, which had an LRF of >6.9 log (Table ) …”

Section: Resultsmentioning

confidence: 89%

Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light

et al. 2020

View full text Add to dashboard Cite

BACKGROUND The INTERCEPT Blood System pathogen reduction technology (PRT), which uses amotosalen and ultraviolet A light treatment (amotosalen/UV‐PRT), inactivates pathogens in plasma and platelet components (PCs). This review summarizes data describing the inactivation efficacy of amotosalen/UVA‐PRT for a broad spectrum of viruses and parasites. METHODS Twenty‐five enveloped viruses, six nonenveloped viruses (NEVs), and four parasites species were evaluated for sensitivity to amotosalen/UVA‐PRT. Pathogens were spiked into plasma and PC at high titers. Samples were collected before and after PRT and assessed for infectivity with cell cultures or animal models. Log reduction factors (LRFs) were defined as the difference in infectious titers before and after amotosalen/UV‐PRT. RESULTS LRFs of ≥4.0 log were reported for 19 pathogens in plasma (range, ≥4.0 to ≥7.6), 28 pathogens in PC in platelet additive solution (PC‐PAS; ≥4.1‐≥7.8), and 14 pathogens in PC in 100% plasma (PC‐100%; (≥4.3‐>8.4). Twenty‐five enveloped viruses and two NEVs were sensitive to amotosalen/UV‐PRT; LRF ranged from >2.9 to ≥7.6 in plasma, 2.4 or greater to greater than 6.9 in PC‐PAS and >3.5 to >6.5 in PC‐100%. Infectious titers for four parasites were reduced by >4.0 log in all PC and plasma (≥4.9 to >8.4). CONCLUSION Amotosalen/UVA‐PRT demonstrated effective infectious titer reduction for a broad spectrum of viruses and parasites. This confirms the capacity of this system to reduce the risk of viral and parasitic transfusion‐transmitted infections by plasma and PCs in various geographies.

show abstract

Ross River Virus Seroprevalence, French Polynesia, 2014–2015

Cited by 17 publications

References 10 publications

Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak

Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak

Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak

Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light

Contact Info

Product

Resources

About